Meiji Holdings Co., Ltd. (2269) Stock Price

Meiji Holdings is a pure holding company consisting of 67 subsidiaries and 8 affiliated companies. The company operates through two main business segments: food and pharmaceuticals.

In the food segment, the company handles yogurt, milk, beverages, cheese, butter, ice cream, prepared foods, chocolate, gummies, sports nutrition, infant formula, nutritional drinks, beauty products, animal feed, and sugar. Major affiliated companies include Meiji Co., Ltd., Meiji Fresh Network Co., Ltd., and Donan Foods Co., Ltd.

In the pharmaceutical segment, the company provides prescription medicines and veterinary drugs. Major affiliated companies include Meiji Seika Pharma Co., Ltd., KM Biologics Co., Ltd., and Taishо Pharmaceutical Co., Ltd. These companies manufacture and sell pharmaceuticals both domestically and internationally.

Meiji Holdings provides diverse products across both food and pharmaceutical sectors and is expanding its business operations domestically and internationally. Through this, the company aims to improve consumer health and quality of life.

Meiji Holdings aims for sustainable growth in the "food and health" sector, with a long-term vision extending through fiscal year 2026. To realize this vision, the company develops three-year medium-term management plans and implements concrete action strategies. The company particularly seeks to create new value in the "health" field and contribute to the overall health of society.

The company's growth strategy focuses on four key priorities: establishing competitive advantages in core businesses, building growth foundations in overseas markets, pursuing new challenges in the health value sector, and contributing to social issues. In the food segment, the company concentrates on core domestic businesses such as yogurt and chocolate, while advancing differentiated product offerings overseas. In the pharmaceutical segment, the company is expanding infectious disease treatments and generic pharmaceuticals, with particular focus on achieving leadership in Asian markets.

The 2026 medium-term management plan prioritizes three strategic initiatives: allocating management resources to growth businesses, maintaining and strengthening stable cash generation capabilities, and advancing human resource strategies aligned with management objectives. In the food segment, the company is expanding overseas operations and utilizing newly developed ingredients. In the pharmaceutical segment, it is strengthening new drug development and supply. Through sustainability activities, the company aims to address social challenges and achieve sustainable growth.